Pronto disponible para inscripción
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

LIMITLESS: Exablate Focused Ultrasound for NSCLC Brain Metastases - Clinical Trial

¿Cuál es el Propósito de este estudio?

If you decide to be part of the study, here's what will happen:

- You'll get check-ups and blood tests.

- Doctors will take pictures of your brain using special machines called CT or MRI.

- Your heart will be checked with a test called an ECG.

- You'll have a special treatment called Exablate to help medicine reach your brain better.

You might get up to 6 rounds of treatment over about 15 weeks, but only if the doctors thinks it's safe to keep going.

¿Cuál es la Condición que se está estudiando?

Brain Metastases of Non-small Cell Lung Cancer (NSCLC) origin

¿Quién puede participar en el Estudio?

Who Can Join the Study (Inclusion Criteria):

- Adults who are 18 years or older.

- People who have a type of lung cancer and are already getting a special kind of medicine called immune therapy.

- Their brain tumors must be very small (less than half a centimeter).

- They must be feeling well enough to do daily activities.

Who Cannot Join the Study (Exclusion Criteria):

- People who have bleeding in the brain or high pressure in the head.

- People who have problems that make them bleed easily.

- People who have had certain types of organ or stem cell transplants.

- People who have a disease that affects the brain and spinal cord.

- People who can't safely get an MRI scan (like if they have metal in their body or are very afraid of small spaces).

Grupo etario
Adultos

¿Qué Implica?

Scientists are doing a study to see if a special treatment called Exablate can help medicine get into brain tumors more easily. They are testing this on people who have lung cancer that has spread to their brain. The goal is to find out if this makes their medicine work better, especially when they are already getting a type of treatment called immune therapy.

Detalles del Estudio

Título Completo
LIMITLESS: A randomized pivotal study assessing the efficacy of targeted blood-brain barrier (BBB) disruption using Exablate focused ultrasound during the standard of care treatment of brain metastases of non-small cell lung cancer (NSCLC) origin
Investigador Principal
Laura Alder, MD
Especialista en oncología médica
Número de Protocolo
IRB: PRO00112599
NCT: NCT05317858
Fase
Phase III
ClinicalTrials.gov
Estado de inscripción
Pronto disponible para inscripción
Más información
Apoye la investigación de Duke Health o rinda homenaje a un ser querido con un regalo conmemorativo.
Contribuya a Duke Health